Asset Details
Do you wish to reserve the book?
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort
Do you wish to request the book?
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort
2025
Overview
Background
Persistence to B cell depleting therapies (BCDT) like ocrelizumab and rituximab may be higher compared with other disease-modifying therapies (DMT) in multiple sclerosis (MS). Clinical trials directly comparing these treatments are lacking.
Objective
To compare the risk of treatment discontinuation, relapse, and confirmed disability worsening in patients starting BCDT vs other DMT within real-world settings.
Methods
In a longitudinal cohort study, patients with relapsing MS starting BCDT (ocrelizumab/rituximab, n = 269) after enrolment into the Swiss MS Cohort (SMSC) were evaluated for treatment discontinuation, occurrence of relapses, and disability worsening in comparison with platform (n = 57) and oral (n = 454) DMT, or natalizumab (n = 73) using Cox regression with double robust adjustment for baseline covariates.
Results
Patients starting BCDT were less likely to discontinue treatment than all other DMT combined (HR = 0.26, 95% CI = 0.18–0.36, p < .01), oral DMT (HR = 0.28, 95% CI = 0.20–0.39, p < .01) and natalizumab (HR = 0.35, 95% CI = 0.21–0.58, p < .01). BCDT were associated with lower risk of relapses as compared to oral DMT HR = 0.59, 95% CI = 0.39–0.88, p < .01), but not to natalizumab (HR = 0.90, 95% CI = 0.45–1.82, p = .778). Disability worsening was not significantly different between treatment groups.
Conclusion
We provide real-world evidence for patients being more persistent to BCDT than to other treatments, and better clinical outcomes may partly explain this.
Publisher
SAGE Publications,Sage Publications Ltd,SAGE Publishing
Subject
